mshelton, Author at Center for U.S. Policy | Page 2 of 49

Understanding Nitazenes and Their Growing Presence in Illicit Drug Markets

Understanding Nitazenes and Their Growing Presence in Illicit Drug Markets

News September 27, 2025

CUSP Comments on FDA Draft Guidance on the Development of Non-Opioid Analgesics for Chronic Pain

CUSP Comments on FDA Draft Guidance on the Development of Non-Opioid Analgesics for Chronic Pain

News September 24, 2025

Pain Does Not Start (or End) in the Brain: Dr. Webster’s Rebuttal to Sanjay Gupta

Pain Does Not Start (or End) in the Brain: Dr. Webster’s Rebuttal to Sanjay Gupta

News September 16, 2025

How Politics in Medicine Harms Patient Care

How Politics in Medicine Harms Patient Care

News September 4, 2025

Beyond Financial Disclosure: Rethinking Conflicts of Interest in Science and Policy

Beyond Financial Disclosure: Rethinking Conflicts of Interest in Science and Policy

News August 18, 2025

FDA Updates Requirements for Opioid Pain Medication Labeling

FDA Updates Requirements for Opioid Pain Medication Labeling

News August 4, 2025

Health Experts Warn CDC Funding Cuts Could Undermine Prevention Efforts

Health Experts Warn CDC Funding Cuts Could Undermine Prevention Efforts

News July 30, 2025

Nationwide Support Solidifies Purdue Pharma’s $7.4 Billion Opioid Settlement

Nationwide Support Solidifies Purdue Pharma’s $7.4 Billion Opioid Settlement

News June 18, 2025

FDA Advisory Committees Review New Evidence on Long-Term Opioid Risks, Prompting Labeling Updates

FDA Advisory Committees Review New Evidence on Long-Term Opioid Risks, Prompting Labeling Updates

News May 28, 2025

Opioid Litigation Status Update

Opioid Litigation Status Update

CUSP Research October 22, 2021